18027209

Source:http://linkedlifedata.com/resource/pubmed/id/18027209

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030351, umls-concept:C0043157, umls-concept:C0220938, umls-concept:C0557061, umls-concept:C1707689, umls-concept:C1883562, umls-concept:C2584313
pubmed:issue	6
pubmed:dateCreated	2007-11-20
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18027209-18027208
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9200436
pubmed:citationSubset	IM
pubmed:status	MEDLINE
pubmed:issn	1054-3406
pubmed:author	pubmed-author:GrendaT JTJJr
pubmed:issnType	Print
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	997-1004; discussion 1029-32
pubmed:meshHeading	pubmed-meshheading:18027209-Clinical Trials as Topic, pubmed-meshheading:18027209-Data Interpretation, Statistical, pubmed-meshheading:18027209-Dose-Response Relationship, Drug, pubmed-meshheading:18027209-Drug Industry, pubmed-meshheading:18027209-Humans, pubmed-meshheading:18027209-Research Design
pubmed:year	2007
pubmed:articleTitle	Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
pubmed:affiliation	Department of Public Health Sciences, King's College, University of London, London, UK. andy.grieve@kcl.ac.uk
pubmed:publicationType	Journal Article, Comment